---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-008489"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:30:09.238211+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma enters research agreement with Georgetown for HDAC6 inhibitor SP-2-225

## Summary
- Research agreement with Georgetown University for up to $128,400 to test SP-2-225 in breast cancer model.
- Agreement runs April 1, 2023 to March 31, 2024; supports IND-enabling studies in 2023.
- Plans to submit IND and start Phase I clinical trial for SP-2-225 in 2024.
- Auditor changed from BF Borgers CPA PC to FORVIS LLP effective March 21, 2023; no disagreements.
- Going concern opinion from 2021 resolved after $11.4M IPO and $4.0M private placement.

## SEC filing metadata
- accession: 0001493152-23-008489
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 4.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315223008489/0001493152-23-008489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315223008489/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-008489
- JSON: https://secwatch.observer/filing/0001493152-23-008489.json
- Plain text: https://secwatch.observer/filing/0001493152-23-008489.txt

## Key facts
- Auditor Changes
  Shuttle Pharmaceuticals Holdings, Inc. engaged FORVIS LLP as its auditor.
  - Action: engagement
  - Auditor: FORVIS LLP
  source text: On March 21, 2023, the Company’s audit committee selected FORVIS LLP (the “New Accountant”) to serve as the Company’s independent registered public accounting firm for the review of its Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315223008489/0001493152-23-008489-index.htm
- Material Agreements
  Shuttle Pharmaceuticals Holdings, Inc. entered into Research Agreement with Georgetown University valued at $128,400 (effective 2023-03-16).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Georgetown University
  - Value: $128,400
  - Effective: 2023-03-16
  source text: On March 16, 2023, Shuttle Pharmaceuticals Inc. (“Shuttle Pharma”), a Maryland corporation and the wholly-owned subsidiary of Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into a research agreement (the “Research Agreement”) with Georgetown University (“Georgetown”) for testing small molecule radiation sensitizers and immune activation candidates discovered and developed by Shuttle Pharma in cell-based and animal xenograft models.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315223008489/0001493152-23-008489-index.htm
- Material Agreements
  Shuttle Pharmaceuticals Holdings, Inc. entered into MTA with Georgetown University (effective 2023-03-21).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Georgetown University
  - Effective: 2023-03-21
  source text: In conjunction with the Research Agreement, Shuttle Pharma entered into a material transfer agreement (the “MTA”), dated March 21, 2023, with Georgetown.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315223008489/0001493152-23-008489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.